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Analysis of prognostic factors and efficacy
of surgical treatment for non-small cell lung cancer:
department of surgery NTLDRI (1998–1999)
Analiza czynników rokowniczych oraz ocena skuteczności
chirurgicznego leczenia niedrobnokomórkowego raka płuca
w Klinice Chirurgii IGiChP w latach 1998–1999
Streszczenie
Wprowadzenie: Postępowanie chirurgiczne stanowi podstawową metodę leczenia niedrobnokomórkowego raka płuca.
Materiał i metody: W pracy przeprowadzono retrospektywną analizę skuteczności tego leczenia w grupie 431 chorych
operowanych w Klinice Chirurgii Instytutu Gruźlicy i Chorób Płuc w Warszawie w latach 1998–1999. W 218 (50%) przypad-
kach wykonano lobektomię, w 21 (5%) — bilobektomię, w 188 (44%) — pneumonektomię, a w 4 (1%) — resekcję klinową.
U 70 (16%) chorych rozpoznano stadium zaawansowania pIA, u 112 (26%) — pIB, u 22 (5%) — pIIA, u 110 (26%) — pIIB,
u 88 (20%) — pIIIA, u 13 (3%) — pIIIB i u 16 (4%) — pIV.
Wyniki: Wskaźnik 5-letniego przeżycia dla całej grupy wynosił 49,1%. Analiza statystyczna wykazała wyższy odsetek
odległych przeżyć w grupie wiekowej do 50. rż. (p = 0,03), u płci żeńskiej (p = 0,01, HR = 0,63), w przypadku mniej
rozległego zabiegu (lobektomia) (p < 0,005). Wskaźniki odległych przeżyć wykazywały znamienną zależność od stadium
zaawansowania choroby nowotworowej (p < 0,005). Pięcioletnie przeżycie pacjentów w stadium IA wynosiło 81,7%, IB —
62,2%, IIA — 59,1%, IIB — 38%, IIIA — 21,3%, IIIB — 8,3% oraz IV — 8,3%. Typ histopatologiczny miał również znamienny
wpływ na odległe przeżycia chorych (p < 0,005). Pięcioletnie przeżycie chorych na raka płaskonabłonkowego wynosiło
53,4%, na raka gruczołowego — 38,3%, na raka wielkokomórkowego — 37,5%, na rakowiaka — 94,7%, a na pozostałe typy
raka — 39,1%. Wskaźnik odległego przeżycia zależał znamiennie od cechy T (p < 0,005). Obniżone wyjściowe stężenie
hemoglobiny (p < 0,005, HR = 1,52) oraz przetoczenie masy erytrocytarnej w okresie pooperacyjnym (p = 0,03) były
niekorzystnymi czynnikami rokowniczymi. Znamiennie gorsze rokowanie wykazano w przypadku cechy R1 lub R2 (p = 0,01)
oraz cechy M1 (p < 0,005). Dodatkowo, w analizie wielowymiarowej Coxa wartość FEV1 poniżej 80% (HR = 1,46) była
zmienną negatywnie wpływającą na odległe przeżycie, a brak objawów klinicznych choroby, z wyjątkiem kaszlu (HR = 0,73)
— zmienną wpływającą korzystnie.
Wnioski: W analizie jednowymiarowej wyłoniono następujące czynniki ryzyka: płeć męska, wiek powyżej 50. rż., obniżone
stężenie Hb, zabieg operacyjny o poszerzonym zakresie, zaawansowane stadium, utkanie raka gruczołowego i wielkokomór-
kowego, cecha T, N, R i M oraz przetoczenie ME w okresie pooperacyjnym. Analiza wielowymiarowa Coxa wykazała
następujące negatywne czynniki prognostyczne: obniżone wyjściowe stężenie Hb, wartość FEV1 poniżej 80%, zabieg opera-
cyjny o poszerzonym zakresie (pneumonektomia), zaawansowane stadium raka, utkanie raka gruczołowego oraz następują-
ce korzystne rokowniczo czynniki: płeć żeńska i brak objawów klinicznych, z wyjątkiem kaszlu.
Słowa kluczowe: niedrobnokomórkowy rak płuca, czynniki prognostyczne, leczenie chirurgiczne, stadium zaawansowania
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Introduction
Lung cancer is the most lethal cancer in the
world [1]. In 2004 in Poland 21 128 cases of lung
cancer were recognized and it was the most frequent
cancer in men [2]. In the US 173 000 new cases of
lung cancer were diagnosed in 2004 [1, 3–5]. Lung
cancer is responsible for approximately 30% of all
cancer deaths [4]. In the US, lung cancer has been
the leading cause of cancer mortality in both men
and women since 1987 [1, 4]. The lung cancer de-
ath rate among men has continued to decrease sin-
ce 1991 [1, 4, 6–8]. In women, most countries show
a rising trend in incidence and mortality due to the
custom of cigarette smoking [9, 10]. Lung cancer
is unique among cancers by having a known etio-
logy and therefore the possibility of risk reduction
by means of smoking cessation [1, 5]. Tobacco
smoking accounts for approximately 90% of the
lung cancer risk, but only 20% of cigarette smo-
kers develope lung cancer [1, 4, 6, 10, 11]. Accor-
ding to current WHO classification, there are four
histological subtypes of lung cancer: squamous cell
carcinoma (40–60% of lung cancers), adenocarci-
noma (25–30%), the incidence of which has incre-
ased since the 1990s, large cell carcinoma (10–15%)
and small cell carcinoma (20%) [10, 11]. First three
types are defined as non-small cell carcinoma
Abstract
Introduction: Surgical resection is the mainstay of curative treatment for non-small cell lung cancer.
Material and methods: A retrospective analysis of the efficacy of this treatment, based on 431 patients operated from 1998
to 1999 in the Department of Surgery of the National Tuberculosis and Lung Diseases Research Institute, was accomplished.
In 218 cases (51%) lobectomy was performed, in 21 cases (5%) — bilobectomy, in 188 cases (44%) — pneumonectomy
and in 4 cases (1%) — wedge resection. The pIA stage was diagnosed in 70 cases (16%), pIB — in 112 (26%), pIIA — in 22
(5%), pIIB — in 110 (26%), pIIIA — in 88 (20%), pIIIB — in 13 (3%) and pIV — in 16 (4%).
Results: The five-year survival rate for the whole group was 49.1%. Statistical analysis revealed better survival in patients
younger than 50 (p = 0.03), in women (p = 0.01, HR = 0.63) and in cases with less extensive surgery, i.e. lobectomy, (p < 0.05).
Long-term survival was significantly dependent on the disease stage (p < 0.005). Five-year survival of patients in stage IA
was 81.7%, IB — 62.2%, IIA — 59.1%, IIB — 38%, IIIA — 21.3%, IIIB — 8.3% and IV — 8.3%. Tumour status (p < 0.005)
and histological subtype (p < 0.005) had a significant influence on long-term survival. Five-year survival of patients with
squamous cell carcinoma was 53.4%, with adenocarcinoma — 38.3%, with large cell carcinoma — 37.5%, with carcinoid
— 94.7% and with other types of cancer — 39.1%. The decreased preoperative Hb level (p < 0.005, HR = 1.52), as well as
blood transfusion in postoperative period (p = 0.03), were negative prognostic factors. Significantly worse prognosis was
observed in the cases of R1 or R2 categories (p = 0.01) and M1 category (p < 0.005). Additionally, in multivariate Cox
analysis, a decreased FEV1 lower than 80% (HR = 1.46) was a negative prognostic factor, and lack of symptoms, except
cough (HR = 0.73), was a positive one.
Conclusions: Univariate analysis revealed several factors worsening prognosis: male sex, age older than 50 years,
lowered preoperative Hb concentration, extended surgery, advanced stage, adenocarcinoma and large cell carcinoma,
T status, N status, R status, M status and blood transfusion in postoperative period. In multivariate Cox analysis lowered
preoperative Hb concentration, decreased FEV1 lower than 80% pred., extended surgery (pneumonectomy), advanced
stage and adenocarcinoma were negative prognostic factors. Female sex and lack of symptoms, except coughing were
positive prognostic factors.
Key words: non-small cell lung cancer, prognostic factors, surgical treatment, staging
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(NSCLC) and constitute 80% of all lung cancer
cases [8, 12, 13]. In North America, unlike in Euro-
pe, adenocarcinoma has become the predominant
type of NSCLC [1, 10, 14]. In 1968 the international
tumour-node-metastasis (TNM) system for cancer
staging was accepted by the Union Internationale
Contre le Cancer (UICC). Since then the revision
of the TNM classification had been repeated every
4–10 years until the fifth edition based on Moun-
tain’s database (5319 cases) was finally enacted in
1997 [11]. In 1999 the Staging Committee of the
International Association for the Study of Lung
Cancer (IASLC) was formed to submit its recom-
mendations to the UICC for the next revision of the
International Staging System for Lung Cancer. It
managed to develop an international database in-
cluding 100 869 lung cancer cases treated betwe-
en 1990 and 2000 from 45 centres in 20 countries
around the globe [15]. The presented material re-
presents our contribution to the IASLC worldwi-
de database in order to enact the sixth revision of
the TNM staging system for NSCLC in 2009. The
choice of therapy of NSCLC depends on the stage
of the disease (cTNM). In Poland 20% of patients
are in stage I or II at diagnosis, 40% — in stage IIIA
or IIIB and the remaining 40% — in stage IV [13,
16]. In early stages of NSCLC (stages I and II) radi-
cal surgery is the treatment of choice [12, 17, 18].
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The best therapeutic option is lobectomy with re-
gional lymph node dissection [12, 17, 19]. Chemo-
therapy and radiotherapy are applied as neoadjuvant
or adjuvant therapy in early stages and constitute sub-
stantial treatment in advanced stages of lung cancer.
In 2004, 3631 out of 21 128 new cases of primary
NSCLC were operated (resection rate — 17.2%) in
Poland. This means that the remaining patients were
offered only non-surgical therapy [2]. Similar resec-
tion rates in Sweden in 1999 were 9.8%, and in Nor-
way in 2002 — 17% [14, 18]. In the US about
35 000 patients with lung cancer a year were offered
surgery [7]. Early detection may be the best way to
improve prognosis, but mass screening including
low-dose spiral chest CT screening remains contro-
versial [7, 17, 19]. The prognosis in lung cancer is
very poor and disappointing with a 5-year survival
of about 10–15%. It has remained unchanged over
the last two decades [1, 8, 11, 12, 14, 18–20]. Relap-
se of the disease occurs in about half of the resec-
ted cases [7, 13]. Failure of treatment is caused by
distant metastases in 75% of cases and by local re-
currences in 25% [16]. We aimed to assess the pro-
gnostic factors of NSCLC after surgery as well as to
evaluate the results of surgical treatment.
Material and methods
The study included 431 consecutive patients
who underwent radical surgery for NSCLC in the
Department of Surgery of the National Tuberculosis
and Lung Diseases Research Institute between Janu-
ary 1998 and December 1999. The following data
from medical records were retrospectively analysed:
— age, gender, smoking status, symptoms, comor-
bidity and performance status;
— blood group and Rh-factor, preoperative Hb, al-
bumin, Ca and serum alkaline phosphatase level;
— site of tumour: right or left lung; peripheral or
central; upper, middle or lower lobe;
— bronchoscopic examination (presence or lack
of endobronchial lesions);
— presence or lack of preoperative histological
diagnosis;
— preoperative lung function (baseline VC and
FEV1 above 80% of pred; 50–80% of pred and
lower than 50% of pred);
— mediastinoscopy;
— extent of surgery (limited resection, lobecto-
my or pneumonectomy);
— postoperative complications;
— postoperative blood transfusion;
— postoperative histological examination: histo-
logical subtype of tumour; tumour size (T sta-
tus); mediastinal lymph nodes status (N dise-
ase); pathological stage of disease (pTNM) and
completeness of resection (R status) according
to TNM system in Mountain modification (5th
edition) from 1997 [12];
— neoadjuvant and adjuvant chemotherapy.
Detailed patient characteristics are presented in
Table 1. Concomitant diseases were: cardiovascular
— 144 (33%) patients, peptic ulcer — 41 (9.5%), dia-
betes — 15 (3.5%), emphysema — 15 (3.5%), CNS
— 9 (2%) and renal — 4 (1%). Two hundred and
two (47%) patients did not suffer from any accom-
panying disease. The performance status of all pa-
tients was satisfactory, i.e. 0 or 1 according to ECOG
scale. Blood groups were as follows: A — 168 (39%)
cases, 0 — 139 (32%), B — 86 (20%) and AB — 38
(9%). Normal albumin concentration was observed
in 422 (98%) patients. Calcium levels were exami-
ned in 130 (30%) patients, and were within nor-
mal limits in the majority of cases (1.03–1.3 mmol/l).
Serum alkaline phosphatase concentrations were
examined in 187 (43%) patients, and were within
limits (91–258 U/l) in 147 (34%) cases, and in
7 cases (1.6%) — even lower than 91 U/l. Only 30
(7%) patients had elevated concentrations of alka-
line phosphatase. In 315 (73%) patients, preope-
rative VC was higher than 80% of pred., and in 93
(21%) it was lower than 80% of pred. In 23 (5%)
cases it was not possible to obtain a spirometry re-
port. Endobronchial lesions occurred in 194 (45%)
patients. Due to mediastinal lymph node enlarge-
ment prior to lung surgery, 153 (35%) patients un-
derwent mediastinoscopy, which was positive in
four cases. Thirty-one (20.8%) out of 149 patients
with negative mediastinoscopy had metastases in
mediastinal lymph nodes (pN2) in postoperative
histological reports. Four patients with positive
mediastinoscopy received neoadjuvant chemothe-
rapy and then underwent surgery (three pneumo-
nectomies and one lobectomy). In three cases, there
were still metastases in mediastinal lymph nodes.
In total, 23 (5%) patients received neoadjuvant
therapy due to both cN1 and cN2. Men underwent
a similar number of pneumonectomies and lobec-
tomies, 152 (47%) and 155 (48%), respectively.
Women underwent twice as many pneumonecto-
mies as lobectomies, 63 (58%) and 36 (33%), re-
spectively. There was a predominance of squamo-
us cell carcinoma in males (62%) with only 28%
of adenocarcinoma. A higher proportion of fema-
les was found to have adenocarcinoma (49%), and
only 27% — squamous cell carcinoma. In the pN2
group, metastases to the following lymph nodes
were revealed: subcarinal in 62 cases, AP window
in 14, lower paratracheal in 13, paraoesophageal
in 6, upper paratracheal in 6, para-aortic in 6,
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pulmonary ligament in 5 and pretracheal in 2.
Sixteen (3.7%) patients presented simultaneous
M1 disease as brain or ipsilateral non-primary
lobe metastasis. Complete resection (R0) was per-
formed in 420 cases (97.4%), and incomplete
resection: R1, in 9 cases (2.1%) and R2 in 2 ca-
ses (0.5%). Seventeen (4%) patients underwent
adjuvant radiotherapy, and 31 (7%) — adjuvant
chemotherapy. Survival curves were calculated
by the Kaplan-Meier method, and significant dif-
ferences in probability of survival were evaluated
by log-rank test. P-values less than 0.05 were
considered statistically significant. Confidence
interval (CI) of 0.95 was accepted. Univariate and
multivariate analysis were performed using Cox
proportional hazards regression model to deter-
mine factors potentially predicting postoperati-
ve survival.
Results
Having excluded 30-day operative mortality,
49.1% of the 431 patients survived for five years.
The median of the whole group was 58.5 months
(95% CI: 41–81). In 307 (71%) cases, the postope-
rative period was uneventful. One hundred and
twenty four (29%) patients developed the follo-
wing postoperative complications: cardiovascular
— in 30 (7%) cases, respiratory — in 26 (6%), ble-
eding — in 16 (4%), empyema — in 16 (4%), wo-
und disruption — in 13 (3%), renal — in 6 (1%)
and psychotic — in 5 (1%). Cardiovascular com-
plication rates of 6% and 10% were noted for lo-
bectomy and pneumonectomy, respectively. No
bronchopleural fistula occurred in lobectomy pa-
tients compared to 4% of those undergoing pneu-
monectomy. For pneumonectomy, higher posto-
Gender/Płeć
Men/Mężczyźni 323 (75%)
Women/Kobiety 108 (25%)
Wiek/Age
< 40 years old 15 (3.5%)
40–49 46 (10.7%)
50–59 118 (27.3%)
60–69 182 (42.2%)
> 70 70 (16.2%)
Smoking status/Palenie tytoniu
No-smokers/Niepalący 67 (16%)
Smokers/Palący 273 (63%)
Not available/Brak danych 91 (21%)
Symptoms/Objawy
Without symptoms/Bezobjawowo 138 (32%)
Cough/Kaszel 176 (41%)
Hemoptoe/Krwioplucie 89 (21%)
Chest pain/Bóle w klatce piersiowej 47 (11%)
Weight loss/Utrata masy ciała 42 (10%)
Pneumonia/Zapalenie płuc 41 (10%)
Hb levels/Hemoglobina
14–16 g/dl — normal/w normie 196 (45%)
< 14 g/dl — decreased/obniżona 236 (55%)
FEV1
Over 80% of pred./Powyżej 80% 208 (48%)
Below 80% of pred./Poniżej 80% 200 (46%)
Site of tumour/Lokalizacja
Peripheral/Obwodowa 294 (68%)
Central/Centralna 137 (32%)
Right upper lobe/Płat górny prawy 127 (29,4%)
Middle lobe/Płat środkowy 21 (5%)
Right lower lobe/Płat dolny prawy 111 (25,7%)
Left upper lobe/Płat górny lewy 99 (22,9%)
Left lower lobe/Płat dolny lewy 73 (16,9%)
Mediastinoscopy/Mediastinoskopia
No/Nie 278 (65%)
Yes/Tak 153 (35%)
Table 1. Patient characteristics
Tabela 1. Charakterystyka pacjentów
N = 431                       N = 431
Type of surgery/Rodzaj zabiegu
Wedge (sublobar) resection/Resekcja klinowa 4 (1%)
Lobectomy/Lobektomia 218 (50%)
Bilobectomy/Bilobektomia 21 (5%)
Pneumonectomy/Pneumonektomia 188 (44%)
Extension of disease/Stadium
IA 70 (16%)
IB 112 (26%)
IIA 22 (5%)
IIB 110 (26%)
IIIA 88 (20%)
IIIB 13 (3%)
IV 16 (4%)
Histology/Utkanie histopatologiczne
Squamous carcinoma/Rak płaskonabłonkowy 229 (53%)
Adenocarcinoma/Rak gruczołowy 144 (33%)
Large cell carcinoma/Rak wielkokomórkowy 16 (4%)
Carcinoid/Rakowiak 19 (5%)
Other NSCLC/Rak niedrobnokomórkowy — inne 23 (5%)
pT status/Cecha T
T1 112 (26%)
T2 254 (59%)
T3 51 (12%)
T4 14 (3%)
pN disease/Cecha N
N0 220 (51%)
N1 129 (30%)
N2 82 (19%)
M status/Cecha M
M0 415 (96.2%)
M1 16 (3.7%)
R status/Cecha R
R0 420 (97.4%)
R1 9 (2.1%)
R2 2 (0.5%)
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perative bleeding rates of 7% were observed. For
lobectomy, postoperative air leak rate was 11%.
Postoperative transfusion was administered in 160
(37%) cases. Postoperative death, i.e. death within
30 days following operation, occurred in five
(1.2%) cases. Death after lobectomy happened in
one (0.4%) case, and after pneumonectomy — in
four (2.1%) cases. The status of all patients (alive
or deceased) was confirmed thanks to precise in-
formation from the City Hall registry. Two hun-
dred and forty-two (56%) patients died, and 189
(44%) are still alive. Survivors were: in stage IA
— 51 (27%) patients, IB — 63 (33%), IIA — 13
(7%), IIB — 40 (21%), IIIA — 19 (10%), IIIB — 1
(0.5%) and IV — 2 (1%). Favourable survival was
observed in patients less than 50 years old (p =
0.03). There were significant differences in survi-
val (p=0.01) between females (5-year survival,
58.9%) and males (5-year survival, 45.4%). Redu-
ced preoperative Hb levels were a negative pro-
gnostic factor (p < 0.005). A significant differen-
ce in survival according to the extent of surgery
was demonstrated (p < 0.005). Five year survival
rate was 56.7% and 38.0% for lobectomy and for
pneumonectomy, respectively. The prognosis de-
pended also on stage of tumour (p < 0.005), the
5-year survival was: 81.7% in stage IA, 62.2% —
IB, 59.1% — IIA, 38% — IIB, 21.3% — IIIA, 8.3%
— IIIB and 8.3% — IV (Fig. 1). Subtype of chest
tumours significantly influenced long-term survi-
val (p < 0.005). Five year survival of patients with
squamous cell carcinoma was 53.4%, adenocar-
cinoma — 38.3%, large cell carcinoma — 37.5%,
carcinoid — 94.7% and other subtypes — 39.1%
(Fig. 2). T status significantly influenced progno-
sis (p < 0.005). Five year survival for patients with
T1 was 67.6%, T2 — 42.4%, T3 — 24.5% and T4
— 7.7% (Fig. 3). There were significant differen-
ces in N factor group (p < 0.005). Five year survi-
val for patients with N0 was 57.3%, N1 — 35% and
N2 — 10.2% (Fig. 4). The following parameters did
not influence survival in univariate analysis: smo-
king (p = 0.33), symptoms — cough (p = 0.19), he-
moptoe (p = 0.39), pneumonia (p = 0.99), weight
loss (p = 0.72) or pain (p = 0.13), comorbidity
(p = 0.16), blood group (p = 0.40), Rh-factor (p =
= 0.74), serum alkaline phosphatase level (p = 0.57),
left or right site of tumour (p = 0.50), central or
peripheral tumour localization (p = 0.79), upper,
middle or lower lobe tumour localization (p =
= 0.11), presence of endobronchial lesion (p = 0.74),
presence of preoperative histological diagnosis
(p = 0.98) and performance of mediastinoscopy
(p = 0.17). Postoperative blood transfusion was
a negative prognostic factor (p = 0.03). Worse pro-
gnosis was combined with incomplete resection
(p = 0.01) and M1 disease (p < 0.005). Five year
survival for R0 was 49.8%, for R1 — 25%, and for R2
— 0% (Fig. 5). Five year survival for M0 was 50%
and for M1 — 18.8%. Multivariate analysis revealed
the following negative prognostic factors (Tab. 2):
preoperative Hb level lower than 14 g/dl
Figure 1. Kaplan-Meier survival curves for patients stratified on the basis of staging
Rycina 1.  Krzywe przeżycia Kaplana-Meiera w zależności od stadium zaawansowania
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(HR = 1.52), decreased FEV1 lower than 80% of
pred. (HR = 1.46), extended surgery (pneumonec-
tomy) (HR = 1.42), adenocarcinoma (HR = 1.99)
and advanced tumour stage pTNM (HR = 2.01).
According to Cox analysis, it was proven that po-
sitive prognostic factors were: gender (women far
better) (HR = 0.63) and lack of clinical symptoms,
except cough (HR = 0.73).
Discussion
The 5-year survival rate of 49.1% of 431 lung
cancer patients who underwent surgery was simi-
lar to those reported in other studies, which gene-
rally range between 30–40% [8, 12, 21, 22]. British
authors noted 5-year survival rate of 30.8% in 329
lung cancer patients, Norwegian — 43.7% in 536
Figure 2. Kaplan-Meier survival curves for patients stratified on the basis of histological type
Rycina 2. Krzywe przeżycia Kaplana-Meiera w zależności od typu histologicznego guza
Figure 3. Kaplan-Meier survival curves for patients stratified on the basis of T status (pT)
Rycina 3. Krzywe przeżycia Kaplana-Meiera w zależności od cechy pT
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patients and Japanese — 52.6% in 6,644 patients
[9, 18, 23]. Similar to our observations, the percen-
tage of males and females with NSCLC was 70%
and 30% in the Japanese study, respectively [23].
Damhuis et al. reported a 30-day operative mor-
tality rate of 3.1%, Ghosh et al. — 3.9%, Doddoli et
al. — 2.8% and Wada et al. — 1.3% [9, 22, 24–26].
We observed a similar postoperative mortality rate
of 1.2%. Alpard et al. noticed mortality rates of 2.7%
and 7.8% for lobectomy and pneumonectomy, re-
spectively [12]. Japanese researchers noted 30-day
operative mortality rates of 1.2% and 3.2% for lo-
bectomy and pneumonectomy, respectively [25].
Our data showed 30-day operative mortality rates
Figure 4. Kaplan-Meier survival curves for patients stratified on the basis of N disease (pN)
Rycina 4. Krzywe przeżycia Kaplana-Meiera w zależności od cechy pN
Figure 5. Kaplan-Meier survival curves for patients stratified on the basis of R status
Rycina 5. Krzywe przeżycia Kaplana-Meiera w zależności od cechy R
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of 0.4% and 2.12%, for lobectomy and pneumonec-
tomy, respectively. Such satisfying results were
achieved mainly due to careful surgical technique
(little blood loss) and accurate postoperative care.
Paroxysmal atrial fibrillation is the most
common complication other than air leak. It oc-
curs in about 20% of patients after lung cancer
resection with peak onset on the second posto-
perative day. Its occurrence is associated with
longer hospital stay, higher costs and higher in-
hospital mortality [27]. Alpard et al. reported car-
diovascular complication rates of 8.5% and 40%
for lobectomy and pneumonectomy, respective-
ly. Bronchopleural fistula occurred in 0.3% of lo-
bectomy patients compared to 6.2% of those un-
dergoing pneumonectomy [13]. In our material,
the rates of cardiovascular complications and
bronchopleural fistula were slightly lower than
in literature, and these complications occurred
more frequently after pneumonectomy (extended
operation).
Van Zandwijk et al., Goya et al. and other au-
thors demonstrated better long-term survival in
women, also confirmed by our univariate and
multivariate analysis [10, 21, 23, 26, 28]. This phe-
nomenon might be explained by the reduced life
expectancy of men due to their higher incidence
of cardiovascular diseases, and extended proce-
dures (pneumonectomy) due to centrally located
squamous cell carcinoma [4, 18]. Olak et al. un-
derlined women’s increased susceptibility to lung
cancer, which might be the result of increased su-
sceptibility to the carcinogens in tobacco smoke,
differences in nicotine metabolism, higher frequ-
ency of gene mutations, reduced capacity to
repair damaged DNA and hormonal factors
(oestrogen) [1, 4, 5].
Berardi et al., Doddoli et al., Goya et al., Ra-
dzikowska et al. and Wada et al. demonstrated
worse prognosis in older patients, which was also
confirmed in the presented study [22, 23, 26, 28–
–30]. However, Ghosh et al. did not prove that age
influenced survival [9]. Surprisingly, our results
were opposite to the Turkish observations that
smoking had a negative influence on survival in
Cox analysis [31]. In the present study, coughing
was the main presenting symptom of lung cancer
(41%) which made the patients visit family doctors.
This was in accordance with other authors
(33–46%) [14].
Cangir et al., similar to our data, confirmed the
significant influence of reduced lung function (FEV1
< 60% of pred.) on prognosis in univariate and
multivariate analysis [31]. Wassawa-Kintu et al.
pointed out that reduced FEV1 was a significant risk
factor for lung cancer, probably due to impaired
ability to clear inhaled carcinogens from airways in
lung dysfunction [5]. Many authors recommended
a predicted postresectional FEV1 of 1.0 L [10].
Our observations were similar to the study car-
ried out by Wada et al., which confirmed that pN
and R status had prognostic significance [29]. Ro-
stad et al. also noted better survival in patients of
free resection margins [18]. Other authors also un-
derlined the prognostic value of N status [30, 31].
In the literature two different techniques of lym-
phadenectomy were applied: a systematic lymph
node dissection (MLND), consisting of all media-
Table 2. Model of multivariate Cox analysis (hazard ratio, confidence interval)
Tabela 2. Model wielowymiarowej analizy Coxa (iloraz ryzyka, przedział ufności)
Parameter Hazard ratio 95% confidence interval p value
Parametr Iloraz ryzyka 95% przedział ufności Wartość p
Female sex/Płeć żeńska 0.63 0.43–0.91 0.01
Lack of clinical symptoms, except coughing 0.73 0.55–0.97 0.03
Brak objawów klinicznych, z wyjątkiem kaszlu
Hb < 14g/dl 1.52 1.15–2.01 < 0.005
FEV1 < 80% 1.46 1.10–1.92 0.01
Pneumonectomy/Pneumonektomia 1.42 1.05–1.92 0.02
Adenocarcinoma/Rak gruczołowy 1.99 1.44–2.75 < 0.005
Stage IB/Stadium IB 2.01 1.14–3.55 0.02
Stage IIA/Stadium IIA 1.48 0.62–3.55 0.38
Stage IIB/Stadium IIB 3.06 1.74–5.39 < 0.005
Stage IIIA/Stadium IIIA 5.26 3.01–9.20 < 0.005
Stage IIIB/Stadium IIIB 7.38 3.39–16.08 < 0.005
Stage IV/Stadium IV 5.98 2.75–13.02 < 0.005
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stinal fatty tissue with lymphatics, and systematic
lymph node sampling (MLNS), consisting of the
removal of at least six lymph nodes from different
stations. The arguments in favour of MLND were:
more accurate staging, eradication otherwise un-
detected micrometastases, better local control and
even improved survival [26, 32]. The argument
against MLND was possibility of higher morbidi-
ty, e.g. bronchopleural fistula, phrenic and recur-
rent laryngeal nerve injury, chylothorax and hemo-
thorax. In our department, different surgeons ap-
plied different methods of lymphadenectomy, but
this issue was not separately analyzed.
T status is an unquestionable factor determi-
ning survival, confirmed by many authors such as
Ghosh et al., Cangir et al., Doddoli et al. and Berar-
di et al. [9, 26, 30, 31]. In the present study we took
the definition of T category from the Mountain 5th
edition of TNM from 1997. However, many authors
proposed re-definition of T1 criteria as tumours
smaller than 2 cm and upgrading lesions larger than
5 cm to T3 according to Carbone’s suggestion or to
T2B according to Watanabe’s ideas [31]. It was also
suggested that tumours invading only the parietal
pleura should be classified as T2, and tumours in-
vading the phrenic nerve or vagus nerve, subcla-
vian vessels or brachial plexus should be upgra-
ded to T4 designation [33]. In our material, the
influence of the exact size of tumour on survival
was not analysed. It was only proven that the bet-
ter survival rate was associated with tumours up
to 3 cm in size (pT1).
In terms of prognosis, tumour stage as summa-
rized in the TNM-system is the most important pro-
gnostic factor in the opinion of many authors [3, 10,
12, 18, 21, 22, 28, 31]. Increasing stage correlates
with a worse prognosis. Similarly to our results,
Naruke et al. demonstrated overlapping prognoses
of patients with neighbouring stages: IB — 59.9%
and IIA — 57.2% [3, 33]. In addition, Goya et al.
revealed very similar long-term survival rates of
patients in stages IB and IIA (60.1% and 59.9%, re-
spectively), and in stages IIIB and IV (19.3% and
20.0%, respectively) [23]. Many authors noticed the
relatively small number of patients in stage IIA, this
observation was confirmed also in the present stu-
dy [22, 33, 34]. These findings indicate the need
to revise the stage grouping. Naruke et al. and Ike-
da et al. showed a favourable 5-year survival rate
of 80% in stage IA, contrary to the figure of 24% in
stage IIIA [3, 19]. Alpard et al. and Dancey et al.
reported the following 5-year survival rates: 70–
–75% in stage I, 30–40% — II and 10–20% — III
[8, 12]. Considering the poor prognosis in NSCLC,
except for stage IA, some authors suggested a mul-
tidisciplinary approach (chemo and radiotherapy)
in early stages of disease, i.e. IIA and IIB [3, 8, 35].
In our material, females developed mainly ade-
nocarcinoma (49%), while squamous cell carcino-
ma predominated in males (62%), similar to the
prospective trial of Koyi et al. and to the study by
Rostad et al. [14, 18]. Van Zandwijk et al. and Na-
ruke et al. revealed better long-term survival in
cases of squamous cell carcinoma, similar to our
univariate and multivariate results [3, 21]. The
observations of Alpard et al., Ghosh et al. and Be-
adsmoore et al. are alike [9, 11, 12, 22]. Contrary
to our results, Japanese researchers have demon-
strated better prognosis in patients with adenocar-
cinoma [23].
Wada et al. reported 8.3% pneumonectomies
and 79% lobectomies in a group of 7 099 patients
with NSCLC [25]. In the literature, the current per-
centage of pneumonectomies stands at approxima-
tely 20% [12]. However, Ponn et al. reported 23–
–53% pneumonectomies in patients with N2 di-
sease treated by induction therapy [36]. In our re-
trospective material, the extent of the lung can-
cer forced the surgeons to perform pneumonecto-
my in 44% of cases as 32% of patients had cen-
trally located lesions and 45% of them had endo-
bronchial lesions. Almost half of all the patients
were in stages IIB or IIIA. Rostad et al. underlined
that pneumonectomy was associated with incre-
ased rate of postoperative complications and mor-
tality in comparison with lobectomy [18]. Many
authors suggested that pneumonectomy, as an
extended resection, was a negative prognostic fac-
tor [31].
Italian researchers concluded that Hb levels
lower that 10 g/dl were a negative prognostic fac-
tor in resected lung cancer patients [30]. Similar
results were obtained in univariate and multiva-
riate analyses of the presented study. Authors re-
ported that about 40% of operated patients requ-
ire postoperative blood transfusion, which was in
accordance with our results (37%). As allogenic
blood transfusion can, to a certain extent, expose
patients to blood-borne viruses such as HBV, HCV
and HIV, care should be taken to limit the amount
of blood given perioperatively [9]. Ghosh et al. no-
ted worse survival in patients with adenocarcino-
ma who underwent radical resection and required
blood transfusion due to frequent relapse [9]. Con-
trary to our data, Berardi et al. did not observe any
association between blood transfusion and survival
after lung cancer resection, and did not advise pre-
operative correction of anaemia [30, 37].
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Conclusions
Univariate analysis revealed several factors wor-
sening prognosis: male sex, age older than 50 years,
lowered preoperative Hb concentration, extended
surgery, advanced stage, adenocarcinoma and large
cell carcinoma, T status, N status, R status, M status
and blood transfusion in postoperative period.
In multivariate Cox analysis: lowered preopera-
tive Hb concentration, decreased FEV1 lower than
80% pred., extended surgery (pneumonectomy), ad-
vanced stage and adenocarcinoma were negative pro-
gnostic factors. Female sex and lack of symptoms,
except coughing were positive prognostic factors.
The five-year survival rate for the whole gro-
up was 49.1%. Five-year survival of patients in sta-
ge IA was 81.7%, IB — 62.2%, IIA — 59.1%, IIB —
38%, IIIA — 21.3%, IIIB — 8.3% and IV — 8.3%.
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